US-based global healthcare company Abbott (NYSE: ABT) announced on Thursday a new, first-of-its-kind clinical trial designed to improve results in patients with worsening heart failure who could benefit from advanced therapy options.
The TEAM-HF trial, which is planned to enrol up to 850 patients across 75 sites worldwide, will measure pulmonary artery pressures (PAP) using Abbott's CardioMEMS HF System to objectively identify advanced heart failure patients at high risk of mortality who could benefit from a life-saving HeartMate 3 left ventricular assist device (LVAD, or heart pump) earlier in their disease progression.
Jennifer Cowger, MD, medical director of mechanical circulatory support and section head of the advanced heart failure program at Detroit-based Henry Ford Health, and one of the national co-principal investigators for the TEAM-HF trial, said: "The goal of the TEAM-HF trial is simple in concept but critical to the future care of patients. We want to break down patient care silos, offering a unified effort to not only improve the diagnosis of advanced heart failure, but also enable rapid access to life saving heart pumps.
"This study aims to take the guess work out of deciding when a patient has reached the ideal time for LVAD implementation. Too many patients are not receiving timely access to this life-saving therapy and are needlessly dying of heart failure. The importance of patient access to multidisciplinary heart failure care is embodied in the trial acronym -- TEAM-HF -- and we feel this study will be instrumental in helping providers identify patients who may benefit from a heart pump earlier in their care journey."
ICU Medical establishes JV with Otsuka Pharmaceutical Factory
FDA Panel supports IceCure's ProSense Cryoablation for early-stage breast cancer
Naitive Technologies enters strategic agreement with Parvizi Surgical Innovation
Akura Medical's application for trial of Katana Thrombectomy System receives US FDA approval
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
PharmaNutra signs agreement with strategic consulting firm for US development plan
BD launches advanced Intraosseous Vascular Access System for rapid emergency use
Pulsenmore to supply 25,000 home ultrasound devices to Clalit Health Services
Medtronic announces new, long-term data from SPYRAL HTN-ON MED clinical trial
Senzime unveils next-gen TetraGraph TOF monitor at ANESTHESIOLOGY 2024; US shipments to begin in Q4
Abbott launches new clinical trial to improve results in patients with advanced heart failure
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Adocia patents stable hormone combinations for obesity and diabetes
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration